Open AccessAcalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
Author(s) -
А А Петренко,
Петренко Андрей Анатольевич,
Maria Kislova,
Кислова Мария Игоревна,
Elena Dmitrieva,
Дмитриева Елена Александровна,
Eugene Nikitin,
Никитин Евгений Александрович
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.2.200957
Subject(s) - ibrutinib , chronic lymphocytic leukemia , medicine , bruton's tyrosine kinase , tolerability , pharmacology , adverse effect , oncology , tyrosine kinase , leukemia , receptor
Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients with CLL. Acalabrutinib was developed as a more selective Bruton tyrosine kinase inhibitor then ibrutinib. This drug is aimed at reducing the adverse events that limit the use of ibrutinib, such as atrial fibrillation and bleeding. Phase I/II multicenter studies have demonstrated the efficacy and safety of acalabrutinib monotherapy in untreated CLL patients and in patients with relapsed/refractory CLL and ibrutinib intolerance. Phase III trials, ASCEND and ELEVATE-TN, compared acalabrutinib monotherapy and a combination of acalabrutinib and obinutuzumab versus standard therapies and demonstrated improved efficacy and tolerability of acalabrutinib. A phase III trial comparing acalabrutinib and ibrutinib monotherapy (ELEVATE-RR) is ongoing. The results of this study along with real-life clinical data could determine the place of acalabrutinib in CLL treatment.